Medtronic plc, a leader in medical technology, has announced receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Visualase™ V2 MRI-Guided Laser Ablation System. This clearance marks a significant advancement in the Visualase™ platform, enhancing its capabilities as a minimally invasive surgical option for treating conditions such as focal epilepsy, brain tumors, and radiation necrosis. With redesigned software and hardware, the V2 system offers improved precision, accuracy, and visualization, allowing for efficient workflows and real-time MRI guidance. This innovation promises reduced hospital stays, faster recovery, minimal scarring, lower infection risks, and high patient satisfaction.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。